Optimizing combination therapies with existing and future CML drugs

PLoS ONE

Volumn 5, Issue 8, 2010, Pages

  Katouli, Allen A ^a   Komarova, Natalia L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DASATINIB; IMATINIB; NILOTINIB; SGX 70393; UNCLASSIFIED DRUG;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL DEATH; CELL DIVISION; CHRONIC MYELOID LEUKEMIA; CLINICAL PROTOCOL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; GENETIC ALGORITHM; IN VITRO STUDY; MUTATION RATE; POINT MUTATION; PROCESS OPTIMIZATION; STOCHASTIC MODEL; TREATMENT PLANNING; ALGORITHM; BIOLOGICAL MODEL; DRUG RESISTANCE; GENETICS; HUMAN; MULTIDRUG RESISTANCE; MUTATION; PROBABILITY; STATISTICS; TREATMENT OUTCOME;

ALGORITHMS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MODELS, BIOLOGICAL; MUTATION; PROBABILITY; STOCHASTIC PROCESSES; TREATMENT OUTCOME;

EID: 77957864516     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012300     Document Type: Article

References (68)

1. Bradeen HA, Eide CA, O'Hare T, Johnson KJ, Willis SG, et al. (2006) Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 108: 2332-8.
2. O'Hare T, Eide CA, Tyner JW, Corbin AS, Wong MJ, et al. (2008) SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc Natl Acad Sci U S A 105: 5507-12.
3. Calabretta B, Perrotti D (2004) The biology of CML blast crisis. Blood 103: 4010-22.
4. Melo JV, Hughes TP, Apperley JF (2003) Chronic myeloid leukemia. Hematology (Am Soc Hematol Educ Program). pp 132-52.
5. Shet AS, Jahagirdar BN, Verfaillie CM (2002) Chronic myelogenous leukemia: mechanisms underlying disease progression. Leukemia 16: 1402-11.
6. Yoshida C, Melo JV (2004) Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease. Int J Hematol 79: 420-33.
7. Xie Y, Davies SM, Xiang Y, Robison LL, Ross JA (2003) Trends in leukemia incidence and survival in the United States (1973-1998). Cancer 97: 2229-35.
8. Moloney WC (1987) Radiogenic leukemia revisited. Blood 70: 905-8.
9. Deininger MW, O'Brien SG, Ford JM, Druker BJ (2003) Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 21: 1637-47.
10. Loriaux M, Deininger M (2004) Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. Leuk Lymphoma 45: 2197-203.
11. Daub H, Specht K, Ullrich A (2004) Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov 3: 1001-10.
12. Druker BJ (2003) Overcoming resistance to imatinib by combining targeted agents. Mol Cancer Ther 2: 225-6.
13. Druker BJ (2004) Imatinib as a paradigm of targeted therapies. Adv Cancer Res 91: 1-30.
14. Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, et al. (2003) Molecular mechanisms of resistance to imatinib in Philadelphiachromosome- positive leukaemias. Lancet Oncol 4: 75-85.
15. Nardi V, Azam M, Daley GQ (2004) Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol 11: 35-43.
16. Shannon KM (2002) Resistance in the land of molecular cancer therapeutics. Cancer Cell 2: 99-102.
17. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, et al. (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354: 2531-41.
18. Deininger MW (2007) Optimizing therapy of chronic myeloid leukemia. Exp Hematol 35: 144-54.
19. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD (2007) Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 7: 345-56.
20. Apperley JF (2007) Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8: 1018-29.
21. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, et al. (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354: 2542-51.
22. Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, et al. (2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110: 4055-63.
23. Deguchi Y, Kimura S, Ashihara E, Niwa T, Hodohara K, et al. (2008) Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk Res 32: 980-3.
24. Quintas-Cardama A, Kantarjian H, Jones D, Nicaise C, O'Brien S, et al. (2007) Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 109: 497-9.
25. Vajpai N, Strauss A, Fendrich G, Cowan-Jacob SW, Manley PW, et al. (2008) Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/ nilotinib and dasatinib. J Biol Chem 283: 18292-302.
26. Hantschel O, Rix U, Superti-Furga G (2008) Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 49: 615-9.
27. Weisberg E, Catley L, Wright RD, Moreno D, Banerji L, et al. (2007) Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood 109: 2112-20.
28. O'Hare T, Eide CA, Deininger MW (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110: 2242-9.
29. Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, et al. (2007) MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109: 500-2.
30. Zhou T, Parillon L, Li F, Wang Y, Keats J, et al. (2007) Crystal structure of the T315I mutant of AbI kinase. Chem Biol Drug Des 70: 171-81.
31. Modugno M, Casale E, Soncini C, Rosettani P, Colombo R, et al. (2007) Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer Res 67: 7987-90.
32. Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, et al. (2008) Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 111: 4355-64.
33. Zhang J, Adrian FJ, Jahnke W, Cowan-Jacob SW, Li AG, et al. (2010) Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463: 501-6.
34. Gontarewicz A, Brummendorf TH (2010) Danusertib (formerly PHA-739358) - A Novel Combined Pan-Aurora Kinases and Third Generation Bcr-Abl Tyrosine Kinase Inhibitor. Recent Results Cancer Res 184: 199-214.
35. Noronha G, Cao J, Chow CP, Dneprovskaia E, Fine RM, et al. (2008) Inhibitors of ABL and the ABL-T315I mutation. Curr Top Med Chem 8: 905-21.
36. Goldie JH, Coldman AJ (1979) A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727-33.
37. Goldie JH, Coldman AJ (1983) A model for resistance of tumor cells to cancer chemotherapeutic agents. Mathematical Biosciences 65: 291-307.
38. Goldie JH, Coldman AJ (1983) Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treat Rep 67: 923-31.
39. Coldman AJ, Goldie JH (1985) Role of mathematical modeling in protocol formulation in cancer chemotherapy. Cancer Treat Rep 69: 1041-8.
40. Coldman AJ, Goldie JH (1986) A stochastic model for the origin and treatment of tumors containing drug-resistant cells. Bull Math Biol 48: 279-92.
41. Moolgavkar SH, Knudson AG Jr (1981) Mutation and cancer: a model for human carcinogenesis. J Natl Cancer Inst 66: 1037-52.
42. Moolgavkar SH, Dewanji A, Venzon DJ (1988) A stochastic two-stage model for cancer risk assessment. I. The hazard function and the probability of tumor. Risk Anal 8: 383-92.
43. Moolgavkar SH (1989) A two-stage carcinogenesis model for risk assessment. Cell Biol Toxicol 5: 445-60.
44. Kimmel M, Axelrod DE (1990) Mathematical models of gene amplification with applications to cellular drug resistance and tumorigenicity. Genetics 125: 633-44.
45. Kimmel M, Stivers DN (1994) Time-continuous branching walk models of unstable gene amplification. Bull Math Biol 56: 337-57.
46. Harnevo LE, Agur Z (1991) The dynamics of gene amplification described as a multitype compartmental model and as a branching process. Math Biosci 103: 115-38.
47. Harnevo LE, Agur Z (1993) Use of mathematical models for understanding the dynamics of gene amplification. Mutat Res 292: 17-24.
48. Roeder I, Glauche I (2008) Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia-insights from mathematical model analyses. J Mol Med 86: 17-27.
49. Cojocaru L, Agur Z (1992) A theoretical analysis of interval drug dosing for cellcycle- phase-specific drugs. Math Biosci 109: 85-97.
50. Gaffney EA (2005) The mathematical modelling of adjuvant chemotherapy scheduling: incorporating the effects of protocol rest phases and pharmacokinetics. Bull Math Biol 67: 563-611.
51. Gaffney EA (2004) The application of mathematical modelling to aspects of adjuvant chemotherapy scheduling. J Math Biol 48: 375-422.
52. Gardner SN, Fernandes M (2003) New tools for cancer chemotherapy: computational assistance for tailoring treatments. Mol Cancer Ther 2: 1079-84.
53. Jackson TL, Byrne HM (2000) A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy. Math Biosci 164: 17-38.
54. Byrne HM, Chaplain MA (1995) Growth of nonnecrotic tumors in the presence and absence of inhibitors. Math Biosci 130: 151-81.
55. Jaffrezou JP, Chen G, Duran GE, Kuhl JS, Sikic BI (1994) Mutation rates and mechanisms of resistance to etoposide determined from fluctuation analysis. J Natl Cancer Inst 86: 1152-8.
56. Kendal WS, Frost P (1988) Genomic instability, tumor heterogeneity and progression. Adv Exp Med Biol 233: 1-4.
57. Michor F, Nowak MA, Iwasa Y (2006) Evolution of resistance to cancer therapy. Curr Pharm Des 12: 261-71.
58. de Pillis LG, Gu W, Fister KR, Head T, Maples K, et al. (2007) Chemotherapy for tumors: an analysis of the dynamics and a study of quadratic and linear optimal controls. Math Biosci 209: 292-315.
59. Komarova NL, Wodarz D (2005) Drug resistance in cancer: principles of emergence and prevention. Proc Natl Acad Sci U S A 102: 9714-9.
60. Komarova NL, Katouli AA, Wodarz D (2009) Combination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemia. PLoS One 4: e4423.
61. Katouli AA (2009) Mathematical modeling of drug cross-resistance in cancer. PhD thesis, University of California Irvine, Mathematics.
62. Komarova NL, Wodarz D (2007) Stochastic modeling of cellular colonies with quiescence: an application to drug resistance in cancer. Theor Popul Biol 72: 523-38.
63. Komarova NL, Wodarz D (2007) Effect of Cellular Quiescence on the Success of Targeted CML Therapy. PLoS ONE 2: e990.
64. Komarova N (2006) Stochastic modeling of drug resistance in cancer. J Theor Biol 239: 351-66.
65. McKinnell RG, Parchment RE, Perantoni AO, Pierce GB (1998) The Biological Basis of Cancer, Cambridge University Press.
66. Branford S, Melo JV, Hughes TP (2009) Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 114: 5426-35.
67. Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, et al. (2009) Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 27: 469-71.
68. Cohen RB, Jones SF, Aggarwal C, von Mehren M, Cheng J, et al. (2009) A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24- hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res 15: 6694-701.